West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$316.50 USD
+8.57 (2.78%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $316.68 +0.18 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
WST 316.50 +8.57(2.78%)
Will WST be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
The Zacks Analyst Blog The Gorman-Rupp, Kontoor Brands, Kontoor Brands and Standex International
Buy These 4 Stocks With New Dividend Hikes Amid Market Volatility
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
Align Technology (ALGN) Q3 Earnings Surpass Estimates
Other News for WST
Parnassus Mid Cap Growth FundĀ Q3 2024 Commentary
Decoding West Pharmaceutical Services Inc (WST): A Strategic SWOT Insight
Artisan Global Opportunities Fund Q3 2024 Commentary
Bank of America Securities Remains a Buy on West Pharmaceutical Services (WST)
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)